EHBP1L1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cervical adenocarcinoma line, designed for loss-of-function studies of the EHBP1L1 gene. This polyclonal knockout population carries heterogeneous gene disruptions introduced by CRISPR/Cas9-mediated targeting, providing a robust model to investigate EHBP1L1 function without clonal selection artifacts. The product enables researchers to analyze the collective impact of EHBP1L1 ablation on endocytic trafficking, actin dynamics, and cell migration.
In this model, gene disruptions are introduced in HeLa cells, a widely utilized human cervical adenocarcinoma epithelial line that harbors HPV18 sequences and displays functional inactivation of the p53 and retinoblastoma (Rb) tumor suppressor pathways. These immortalized cells retain key epithelial characteristics and are permissive for studying oncogenic signaling and cytoskeletal organization. Their well-characterized genetic background and robust growth properties make HeLa cells an ideal host for generating knockout populations to dissect molecular mechanisms underlying cancer cell behavior.
EHBP1L1 functions as an endocytic adaptor that physically couples clathrin-mediated endocytosis to the actin cytoskeleton. It engages key endocytic components including Eps15, Intersectin, Clathrin, and the AP-2 complex, while simultaneously linking to actin polymerization machinery. Upstream signals from EGF, PDGF, and integrin receptors are transduced via Rac1 and Cdc42 to regulate EHBP1L1 activity. Downstream, EHBP1L1 coordinates the Arp2/3 complex, Cortactin, and focal adhesion kinase, facilitating actin filament nucleation and membrane deformation. This molecular network ensures efficient vesicle scission by coupling the forces of actin polymerization with the endocytic machinery, and its disruption impairs clathrin-coated vesicle formation and integrin-mediated adhesion dynamics.
In the HeLa cervical cancer background, loss of EHBP1L1 disrupts the coordinated interplay between endocytic trafficking and actin reorganization, leading to defective cell migration and invasion. Given the central role of HPV-driven p53 and Rb inactivation in cervical carcinogenesis, this EHBP1L1 knockout population provides a relevant context to study how endocytic adaptors contribute to metastatic potential. As EHBP1L1 integrates signals from integrins and growth factor receptors, its ablation in HeLa cells may reveal vulnerabilities in cancer cell motility and adhesion that are exploitable for therapeutic intervention.
This EHBP1L1 polyclonal knockout cell population is a versatile tool for investigating clathrin-mediated endocytosis, actin cytoskeleton dynamics, and cancer cell motility. Researchers can employ transferrin uptake assays to quantify endocytic efficiency, wound healing and Transwell migration assays to assess cell motility, and co-immunoprecipitation to map protein interactions within the EHBP1L1 network. Immunofluorescence analysis of cortactin and Arp2/3 localization, combined with Western blotting for focal adhesion kinase activation, enables detailed dissection of downstream signaling. The model also supports drug delivery studies by evaluating how EHBP1L1 loss affects internalization of therapeutic cargoes. For further information or technical support, please contact Ascent Research.
